Literature DB >> 32391421

Emerging role of mRNA epitranscriptomic regulation in chemoresistant cancer cells.

Shensi Shen1, Xiaoxiao Sun2.   

Abstract

Cancer persister cells remain a significant barrier to effective anti-cancer therapy. We found that melanoma persister cells undergo a reversible reprogramming of mRNA translation. A subset of mRNAs, harboring N6-methyladenosine in their 5'-untranslated regions, is translationally up-regulated in an eIF4A-dependent manner. Targeting eIF4A prevents the emergence of resistant clones.
© 2020 Taylor & Francis Group, LLC.

Entities:  

Keywords:  Cancer persister cell; epitranscriptomic; mRNA translation

Year:  2020        PMID： 32391421      PMCID： PMC7199735          DOI： 10.1080/23723556.2020.1728467

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  9 in total

1.  Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?

Authors:  Henrike Tolk; Imke Satzger; Peter Mohr; Lisa Zimmer; Benjamin Weide; Susanne Schäd; Ralf Gutzmer
Journal:  Melanoma Res       Date:  2015-08       Impact factor: 3.599

2.  Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug Exposure.

Authors:  Gulfem Dilek Guler; Charles Albert Tindell; Robert Pitti; Catherine Wilson; Katrina Nichols; Tommy KaiWai Cheung; Hyo-Jin Kim; Matthew Wongchenko; Yibing Yan; Benjamin Haley; Trinna Cuellar; Joshua Webster; Navneet Alag; Ganapati Hegde; Erica Jackson; Tracy Leah Nance; Paul Garrett Giresi; Kuan-Bei Chen; Jinfeng Liu; Suchit Jhunjhunwala; Jeff Settleman; Jean-Philippe Stephan; David Arnott; Marie Classon
Journal:  Cancer Cell       Date:  2017-08-03       Impact factor: 31.743

3.  A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.

Authors:  Sreenath V Sharma; Diana Y Lee; Bihua Li; Margaret P Quinlan; Fumiyuki Takahashi; Shyamala Maheswaran; Ultan McDermott; Nancy Azizian; Lee Zou; Michael A Fischbach; Kwok-Kin Wong; Kathleyn Brandstetter; Ben Wittner; Sridhar Ramaswamy; Marie Classon; Jeff Settleman
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

4.  Toward Minimal Residual Disease-Directed Therapy in Melanoma.

Authors:  Florian Rambow; Aljosja Rogiers; Oskar Marin-Bejar; Sara Aibar; Julia Femel; Michael Dewaele; Panagiotis Karras; Daniel Brown; Young Hwan Chang; Maria Debiec-Rychter; Carmen Adriaens; Enrico Radaelli; Pascal Wolter; Oliver Bechter; Reinhard Dummer; Mitchell Levesque; Adriano Piris; Dennie T Frederick; Genevieve Boland; Keith T Flaherty; Joost van den Oord; Thierry Voet; Stein Aerts; Amanda W Lund; Jean-Christophe Marine
Journal:  Cell       Date:  2018-07-12       Impact factor: 41.582

5.  Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.

Authors:  Sydney M Shaffer; Margaret C Dunagin; Stefan R Torborg; Eduardo A Torre; Benjamin Emert; Clemens Krepler; Marilda Beqiri; Katrin Sproesser; Patricia A Brafford; Min Xiao; Elliott Eggan; Ioannis N Anastopoulos; Cesar A Vargas-Garcia; Abhyudai Singh; Katherine L Nathanson; Meenhard Herlyn; Arjun Raj
Journal:  Nature       Date:  2017-06-07       Impact factor: 49.962

6.  Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition.

Authors:  Matthew J Hangauer; Vasanthi S Viswanathan; Matthew J Ryan; Dhruv Bole; John K Eaton; Alexandre Matov; Jacqueline Galeas; Harshil D Dhruv; Michael E Berens; Stuart L Schreiber; Frank McCormick; Michael T McManus
Journal:  Nature       Date:  2017-11-01       Impact factor: 49.962

Review 7.  Dynamic transcriptomic m6A decoration: writers, erasers, readers and functions in RNA metabolism.

Authors:  Ying Yang; Phillip J Hsu; Yu-Sheng Chen; Yun-Gui Yang
Journal:  Cell Res       Date:  2018-05-22       Impact factor: 25.617

8.  TRAIL-induced variation of cell signaling states provides nonheritable resistance to apoptosis.

Authors:  Reema Baskar; Harris G Fienberg; Zumana Khair; Patricia Favaro; Sam Kimmey; Douglas R Green; Garry P Nolan; Sylvia Plevritis; Sean C Bendall
Journal:  Life Sci Alliance       Date:  2019-11-08

9.  An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells.

Authors:  Shensi Shen; Sara Faouzi; Amandine Bastide; Sylvain Martineau; Hélène Malka-Mahieu; Yu Fu; Xiaoxiao Sun; Christine Mateus; Emilie Routier; Severine Roy; Laurent Desaubry; Fabrice André; Alexander Eggermont; Alexandre David; Jean-Yves Scoazec; Stéphan Vagner; Caroline Robert
Journal:  Nat Commun       Date:  2019-12-16       Impact factor: 14.919
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.